公司概覽
業務類別 Biotechnology
業務概覽 NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is thediscovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
公司地址 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
電話號碼 +1 778 731-1711
傳真號碼 --
公司網頁 https://www.nervgen.com
員工數量 18
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Adam H. Rogers, M.D. Interim Chief Financial Officer, President and Chairman of the Board -- 31/03/2026
 
董事會成員
董事會 職務 更新日期
Dr. Randall E. Kaye,M.D. Director 31/03/2026
Dr. Harold M. Punnett Independent Director 31/03/2026
Mr. Neil A. Klompas, C.A. Independent Director 31/03/2026
Ms. Krista L. McKerracher Independent Director 31/03/2026
Dr. Adam H. Rogers, M.D. Interim Chief Financial Officer, President and Chairman of the Board 31/03/2026
Mr. J. Craig Thompson Lead Independent Director 31/03/2026
Mr. Brian E. Bayley Independent Director 31/03/2026
Mr. Gianni Ruffolo Independent Director 31/03/2026
 
所屬ETF (更新日期: 07/11/2026 02:24)
代號 名稱 佔比% ▼ 持有日期
GWXState Street® SPDR® S&P® Intl Sm Cp ETF0.06%30/10/2026
IBRNiShares Neuroscience and Healthcare ETF0.01%30/10/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.